These four Dividend Aristocrats are Buy-rated sector leaders with yields above 3%. Passive income investors can buy and hold ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus ...

AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes those with acute HCV. This development is significant as it broadens ...

MAVYRET is now approved for both acute and chronic HCV infection in adults and pediatric patients three years and older without cirrhosis or with compensated cirrhosis. While the company maintains ...

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET ® (glecaprevir ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.

In 2019, the FDA approved Mavyret to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes ...

NORTH CHICAGO - The U.S. Food and Drug Administration has approved a label expansion for AbbVie’s (NYSE: ABBV) MAVYRET, making it the first and only oral treatment approved for acute hepatitis C ...

"The FDA’s expanded indication of MAVYRET for acute HCV infection marks a significant milestone for patients with HCV. We are proud that our discovery of glecaprevir contributed to a therapy ...